{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "33789885",
  "DateCompleted": {
    "Year": "2021",
    "Month": "04",
    "Day": "07"
  },
  "DateRevised": {
    "Year": "2023",
    "Month": "08",
    "Day": "04"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2021",
        "Month": "03",
        "Day": "31"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1136/bmj.n858"
    ],
    "Journal": {
      "ISSN": "1756-1833",
      "JournalIssue": {
        "Volume": "372",
        "PubDate": {
          "Year": "2021",
          "Month": "Mar",
          "Day": "31"
        }
      },
      "Title": "BMJ (Clinical research ed.)",
      "ISOAbbreviation": "BMJ"
    },
    "ArticleTitle": "Update to living systematic review on drug treatments for covid-19.",
    "Pagination": {
      "StartPage": "n858",
      "MedlinePgn": "n858"
    },
    "PublicationTypeList": [
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "BMJ",
    "NlmUniqueID": "8900488",
    "ISSNLinking": "0959-8138"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Angiotensin-Converting Enzyme Inhibitors"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Anticoagulants"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antiparasitic Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antirheumatic Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antiviral Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Interleukin-6"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Janus Kinase Inhibitors"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Pharmaceutical Preparations"
    }
  ],
  "CommentsCorrectionsList": [
    {
      "RefSource": "BMJ. 2020 Jul 30;370:m2980",
      "PMID": "32732190"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Angiotensin-Converting Enzyme Inhibitors"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Anticoagulants"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Antiparasitic Agents"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Antirheumatic Agents"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Antiviral Agents"
    },
    {
      "QualifierName": [
        "diagnosis",
        "epidemiology",
        "virology"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "antagonists & inhibitors"
      ],
      "DescriptorName": "Interleukin-6"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Janus Kinase Inhibitors"
    },
    {
      "QualifierName": [
        "supply & distribution"
      ],
      "DescriptorName": "Pharmaceutical Preparations"
    },
    {
      "QualifierName": [
        "statistics & numerical data"
      ],
      "DescriptorName": "Respiration, Artificial"
    },
    {
      "QualifierName": [
        "drug effects",
        "genetics"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Systematic Reviews as Topic"
    },
    {
      "QualifierName": [],
      "DescriptorName": "COVID-19 Drug Treatment"
    }
  ]
}